Mutant forms of cholera holotoxin as an adjuvant

Details Mutant forms of cholera holotoxin as an adjuvant Mutant forms of cholera holotoxin as an adjuvant

2007-10-23

2007-10-23

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C530S350000

Reexamination Certificate

active

10478307

ABSTRACT:
Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.

REFERENCES:
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4883761 (1989-11-01), Keith et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5182109 (1993-01-01), Tamura
patent: 5601831 (1997-02-01), Green et al.
patent: 5643747 (1997-07-01), Baker et al.
patent: 5679352 (1997-10-01), Chong et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 5770203 (1998-06-01), Burnette et al.
patent: 5786189 (1998-07-01), Locht et al.
patent: 5925546 (1999-07-01), Pizza et al.
patent: 5965354 (1999-10-01), Burke et al.
patent: 5972336 (1999-10-01), Michetti et al.
patent: 6040427 (2000-03-01), Locht et al.
patent: 6245337 (2001-06-01), St. Geme, III et al.
patent: 6290962 (2001-09-01), Michetti et al.
patent: 6395964 (2002-05-01), Arntzen et al.
patent: 6514503 (2003-02-01), Gizurarson et al.
patent: 6558677 (2003-05-01), Zollinger et al.
patent: 6685949 (2004-02-01), Gu et al.
patent: 7105161 (2006-09-01), Gajewczyk et al.
patent: 2003/0113345 (2003-06-01), Clements
patent: 2003/0176653 (2003-09-01), Mason et al.
patent: 2004/0176571 (2004-09-01), Green et al.
patent: 2005/0175631 (2005-08-01), Vajdy et al.
patent: 2006/0008476 (2006-01-01), Pizza et al.
patent: 2006/0057155 (2006-03-01), Masignani et al.
patent: 2006/0069052 (2006-03-01), Hone
patent: 2006/0140981 (2006-06-01), Jonsdottir
patent: 2006/0177469 (2006-08-01), Rappuoli
patent: 2006/0251675 (2006-11-01), Hagen
patent: WO-92/19265 (1992-11-01), None
patent: WO-93/13202 (1993-07-01), None
patent: 951722 (1995-06-01), None
patent: WO-95/17211 (1995-06-01), None
patent: WO-96/06627 (1996-03-01), None
patent: WO-97/02348 (1997-01-01), None
patent: WO-97/05267 (1997-02-01), None
patent: WO-97/29771 (1997-08-01), None
patent: WO-98/32461 (1998-07-01), None
patent: 9842375 (1998-10-01), None
patent: WO-98/42375 (1998-10-01), None
patent: WO-98/45324 (1998-10-01), None
patent: WO99/27944 (1999-06-01), None
patent: WO-00/18434 (2000-04-01), None
patent: WO-02/098369 (2002-12-01), None
Jobling, MG et al (Jul. 2001), vol. 183(13), pp. 4024-4032, Biological and Biochemical characterization of variant A subunits of cholera toxin constructed by Site-directed mutagenesis.
Sanchez et al, The Journal of Biological Chemistry, vol. 277, No. 26, Issue of Sep. 6, pp. 33369-33377, 2002.
Pizza, M et al, Mol. Microbiology, Oct. 1994, vol. 14(1), pp. 51-60 (abstract only), Probing the structure-activity relationships ofEscherichia coliLT-A by site directed mutagenesis. (abstract only).
Communications- Supplementary European Search Report in European Application No. EP 02752145, mailed Apr. 21, 2006.
Feil et al., “Protein engineering studies of A-chain loop 47-56 ofEscherichia coliheat-labile enterotoxin point to a prominent role of this loop cytotoxicity”, Mol Microbiol. May 1996, 20(4):823-32.
Jobling et al., “Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras”, Infect Immun. Nov. 1992, 60(11):4915-24.
Lobet et al., “Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit ofEscherichia coliheat-labile enterotoxin”, Infection and Immunity Sep. 1991 59(9):2870-2879.
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, Dec. 7, 1995.
Shi et al., GENBANK Accession No. AAC34728, 1993.
Tebbey et al., “Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H”, Vaccine, Jun. 1, 2000:18(24):2723-34.
Zhang et al., “The three-dimensional crystal structure of cholera toxin”, J Mol Biol. Aug. 25, 1995, 251(4):563-73.
Elson et al., “Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin”,J. Immunol. Jun. 1984 132(6):2736-2741.
Elson et al., “Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen”,J. Immunol. Dec. 1984 133(6):2892-2897.
Glineur et al., “Importance of ADP-ribosylation in the morphological changes of PC12 cells induced by cholera toxin”,Infect. Immun. Oct. 1994 62(10):4175-4185.
Giuliani et al., “Mucosal adjuvanticity and immunogenicity of LTR72, A noval mutant ofEscherichia coliheat labile enterotoxin with partial knockout of ADP-ribosyltransferase activity”,J. Exp. Med. Apr. 1998 187(7):1123-1132.
Jobling, Michael G., “Analysis of the structure and function of cholera toxin A subunit”,Abstracts of the General Meeting-American Society for Microbiology1991 p. 59 Abstract No. B-205.
Jobling et al., “Biological and biochemical characterization of variant A. Subunits of cholera toxin constructed by site-directed mutagenesis”,J. Bacteriol. Jul. 2001 183(13):4024-4032.
Jobling et al., “Identification of motifs in cholera toxin A1 polypeptide that are required for its interaction with human ADP-ribosylation factor 6 in a bacterial two-hybrid system”Proc. Natl. Acad. Sci. USADec. 2000 97(26):14662-14667.
Locht et al., “Probing the structure-function relationship of the pertussis toxin S1 subunit by site-directed mutagenesis” inBacterial Protein Toxins, Supp. 19, Rappuoli et al. (Eds.) Gustav Fischer Verlag, New York 1990 pp. 89-90.
Lycke et al., “Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens”,ImmunologyOct. 1986 59(2):301-308.
McKenzie et al., “Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response”,J. Immunol. Oct. 1984 133(4):1818-1824.
Mekalanos et al., “Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development”,NatureDec. 1983 306:551-557.
Nedrud et al., “Oral immunization against respiratory viruses in mice”,Adv Exp Med. Biol. 1995 371B:1595-1598.
O'Neal et al., “Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin,Escherichia coliheat labile toxin (LT) and LT-R192G induce protection from rotavirus challenge”,J. of Virol. Apr. 1998 72(4):3390-3393.
Pachuk et al., “Humoral and cellular immune responses to herpes simplex virus-2 glycoprotein D generated by facilitated DNA immunization of mice”,Curr. Top. Microbiol. Immunol. 1998 226:79-89.
Pizza et al., “Mucosal vaccines: non-toxid derivatives of LT and CT as mucosal adjuvants”,VaccineMar. 2001 19:2534-2541.
Richards et al., “Enhancement of the immune response to non-replicating herpes simplex virus type-1 preparations by mucosal administration in the presence of cholera toxin”,VaccineJul. 1997 15(10):1065-1069.
Vadheim et al., “Expression and mutagenesis of recombinant cholera toxin A subunit”,Micro. Pathol. Nov. 1994 17(5):339-346.
Yamamoto et al., “Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity”,J. Exp. Med. Apr. 1997 185(7):1203-1210.
Zhu et al., “Intragastric immunization with recombinant H. pylori urease formulated with attenuated cholera toxin elicits systemic, mucosal and protective immune responses in C57BL/6 mice”,FASEB J. Mar. 1999 13(4):A291.
Janeway and Travers (Eds), “The Immune System in Health and Disease” inImmunobiologySecond Edition, Current Biology

Affiliated with

Also associated with

Rating

Mutant forms of cholera holotoxin as an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutant forms of cholera holotoxin as an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant forms of cholera holotoxin as an adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3901280